Market Newsdesk

Oracle Analytics Cloud enables organizations to drive business insights and take smarter actions to lead the new era of AI-powered analytics

AUSTIN, Texas
, June 23, 2025 /PRNewswire/ — Oracle has been named a Leader in the 2025 Gartner® Magic Quadrant™ for Analytics and Business Intelligence Platforms. For the second year in a row, Oracle was recognized for its Ability to Execute and Completeness of Vision. A complimentary copy of the report is available here.

“With the continued rapid growth of data, advancements in AI technology, and the ever-increasing demand for data-driven insights, the field of analytics is transforming businesses in unprecedented ways,” said T.K. Anand, executive vice president, Oracle Analytics. “We feel our position as a Leader is a direct result of Oracle’s commitment to putting AI at the core of our analytics offerings, delivering intelligent, real-time insights that empower our customers to make more confident decisions and drive measurable outcomes.”

Oracle continues to enhance its Analytics Cloud offerings and is applying AI to help people in different roles interact with analytics. For example, Oracle Analytics AI Assistant allows workbook authors and analysts to use natural language to discover interesting insights about their data and build complex visualizations. The AI Assistant is powered by the Oracle Cloud Infrastructure (OCI) Generative AI service. In addition, Contextual Insights enable business users to gain a deeper understanding of their data by offering insights and recommendations as they navigate and explore analytics content.

The future of analytics will be defined by increased automation, more personalization, and a greater emphasis on delivering contextual insights. To address these trends, Oracle is delivering innovation with new solutions and features to lead the new era of AI-powered analytics.

Additional Resources

• Read the Oracle Analytics blog
• Learn more about Oracle Analytics

Gartner Disclaimer
Gartner, Magic Quadrant for Analytics and Business Intelligence Platforms, Anirudh Ganeshan, Edgar Macari, Jamie O’Brien, Kurt Schlegel, Christopher Long, 16 June 2025.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-named-a-leader-in-the-2025-gartner-magic-quadrant-for-analytics-and-business-intelligence-platforms-302487786.html

SOURCE Oracle

Fourth cohort dose is three million CAR positive cells; thirty times higher than the first cohort dose

SAN JOSE, Calif.
, June 23, 2025 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the fourth dosage cohort in the ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center (“Moffitt”) under the direction of Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt, the principal investigator.

The fourth cohort in the trial will receive a dose of three million CAR-positive cells per kilogram of body weight, representing a thirtyfold increase from the first cohort. No dose-limiting toxicities were observed in the third cohort, enabling advancing to the fourth dosage cohort. This planned escalation marks a key step in assessing the safety and therapeutic effect of CAR-T cell therapy in patients with ovarian cancer.

Anixa’s FSHR-mediated CAR-T technology targets the follicle-stimulating hormone receptor (FSHR), which research indicates is exclusively expressed on ovarian cells, tumor vasculature, and certain cancer cells. The first-in-human trial (NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies. The study is designed to evaluate safety, identify the maximum tolerated dose, and monitor efficacy.

Dr. Amit Kumar, Chairman and CEO of Anixa, stated, “With no dose-limiting safety issues observed in the third cohort, we have advanced to a higher dose level that is thirty times greater than the starting dose. Although the study is primarily focused on safety at these early, low-dose levels, we have seen promising signs of potential efficacy. “

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa’s therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company’s vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against “retired” proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa’s unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa’s current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A – Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:

Mike Catelani

President, COO & CFO
[email protected]
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-initiates-dosing-in-fourth-cohort-in-its-ovarian-cancer-car-t-clinical-trial-302487548.html

SOURCE Anixa Biosciences, Inc.

SALT LAKE CITY
, June 23, 2025 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it will host a virtual research and development (R&D) investor event on Wednesday, July 9, 2025 at 11:00 AM ET featuringKristina M. Deligiannidis, MD (Zucker Hillside Hospital, Northwell Health, New York), who will join company management to discuss the current treatment landscape and unmet needs in postpartum depression (PPD). To register, click here. 

PPD is a common and serious mood disorder associated with adverse maternal and infant health outcomes. Effective, fast-acting treatment is critical for the well-being of the family.

The event will highlight Lipocine’s clinical programs with a focus on LPCN 1154 (BRLIZIO^™)¹, a bioidentical to a naturally occurring neuroactive steroid. LPCN 1154 is being developed with the potential to be the first line option for rapid symptom relief in women with PPD. LPCN 1154 is targeted to have a 48-hour treatment duration in an outpatient setting through a convenient oral form.

The event will provide clinical, regulatory, and development updates, including details on the recently initiated Phase 3 registrational study which is expected to read out in Q2-2026.

A live Q&A session will follow the formal presentations.

About Kristina M. Deligiannidis, MD

Kristina M. Deligiannidis, MD received her medical degree from and completed her psychiatry residency and chief residency in psychopharmacology research at the University of Massachusetts Medical School. Prior to and during medical school she trained in neuroscience research at the National Institutes of Health (NIH). After residency she completed additional research training in behavioral endocrinology and experimental therapeutics at the NIH and in multimodal neuroimaging at the Martinos Center for Biomedical Imaging at Mass General Hospital.

Dr. Deligiannidis is the Director of Women’s Behavioral Health at Zucker Hillside Hospital, Northwell Health and a Professor of Psychiatry, Molecular Medicine and Obstetrics and Gynecology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. As a reproductive psychiatrist, she has expertise in treating women with mood and anxiety disorders linked to the menstrual cycle, perinatal and perimenopausal periods.

Dr. Deligiannidis is a nationally recognized leader in the field of perinatal depression and in novel therapeutics research. Her research program includes a focus in neurosteroids and hormones, and multimodal neuroimaging. Dr. Deligiannidis’s research is supported by NIH, foundation, donor and industry funding. For the past decade she served as a principal investigator on the series of clinical trials that led to the FDA approval of two rapid-acting antidepressants for postpartum depression.

Dr. Deligiannidis is a current Board of Directors member for the Marcé of North America, past Council member of the Society of Biological Psychiatry, past Board of Directors member for the American Society of Clinical Psychopharmacology and currently is a full member of the American College of Neuropsychopharmacology. Dr. Deligiannidis also serves as a reviewer on over 20 scientific journals and on Editorial Boards of national and international journals.

About LPCN 1154

LPCN 1154 is an oral formulation of brexanolone in development targeted for administration resulting in rapid relief of PPD. Brexanolone is a bioidentical to naturally occurring neuroactive steroid, allopregnanolone, a positive allosteric modulator of y-aminobutyric acid (GABA) receptor. LPCN 1154 is expected to have characteristics that could be particularly appealing to patients with PPD, acutely elevated suicide risk, and in whom rapid improvement is a priority while presenting no significant risk of adverse reactions to breastfed infants from exposure to brexanolone.

About Postpartum Depression and Unmet Needs

PPD is a major depressive disorder with onset either during pregnancy or within four weeks of delivery, with symptoms persisting up to 12 months after childbirth. Hormonal changes leading to GABA dysfunction are common in depression and pregnancy. Symptoms of PPD include hallmarks of major depression, including, but not limited to, sadness, depressed mood, loss of interest, change in appetite, insomnia, sleeping too much, fatigue, difficulty thinking/concentrating, excessive crying, fear of harming the baby/oneself, and/or thoughts of death or suicide. Results from a recent survey (Truist Securities Research, January 2024) show that obstetricians believe approximately 20-40% of their patients may suffer from PPD. In addition, 64% of women with PPD reported comorbid anxiety symptoms. Further, obstetricians are comfortable making a diagnosis and prescribing antidepressants for PPD. Traditional antidepressants, not approved for PPD, have slow onset of action, side effects such as weight gain, and do not demonstrate adequate remission post-acute treatment.

About Lipocine

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.

Lipocine’s clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.

Forward-Looking Statements

This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product candidates and related clinical trials, our development of our product candidates and related efforts with the FDA, including with respect to LPCN 1154, our P3 safety and efficacy study relating to LPCN 1154, the timing and potential results of the safety and efficacy study relating to LPCN 1154, potential partnering of our product candidates with third parties, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of a NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

¹ Brand name conditionally approved by the FDA

View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-to-host-virtual-rd-investor-event-to-discuss-lpcn-1154-brlizio-as-a-treatment-for-postpartum-depression-on-july-9-2025-302487398.html

SOURCE Lipocine Inc.

Harmonic’s cOS Platform Enables Mediacom to Offer Multigigabit and Symmetrical Services with High Reliability, Lower Operating Costs and a Clear Path to Fiber

SAN JOSE, Calif.
, June 23, 2025 /PRNewswire/ — Harmonic (NASDAQ: HLIT) today announced that Mediacom Communications, the fifth-largest cable operator in the U.S., has chosen Harmonic’s industry-leading cOS^™ virtualized broadband platform to modernize its network. The cOS platform allows Mediacom to offer multigigabit and symmetrical speeds and an enhanced subscriber experience with DOCSIS 4.0 broadband services as well as gain the optionality to add fiber services. This strategic deployment supports Mediacom’s shift to a distributed access architecture (DAA) with Harmonic’s Unified DOCSIS 4.0 solution, providing faster and lower-latency internet experiences for consumers.

“As we prepare our network to embrace the future of broadband, we needed a partner with deep DOCSIS 4.0 expertise and a proven track record,” said JR Walden, CTO at Mediacom. “We chose Harmonic for their clear leadership in innovative technology, unparalleled scalability across diverse deployments and robust installed base. Partnering with Harmonic will enable us to deliver ultra-fast broadband connectivity and outstanding quality of experience leveraging DOCSIS 4.0 technology.”

With this deployment, Harmonic continues to expand its broadband industry leadership. Mediacom joins a growing number of top-tier service providers leveraging Harmonic’s cOS platform — making Harmonic a technology partner of choice for eight of the 10 largest cable broadband operators in the U.S.

Mediacom is deploying Harmonic’s cOS virtualized broadband platform and Ripple modular DAA nodes. By adopting this approach, Mediacom is among the first North American operators to launch DOCSIS 4.0 broadband services leveraging a Unified DOCSIS 4.0 architecture that supports both Full Duplex (FDX) and Frequency Division Duplex (FDD) technologies. The future-ready solution enables Mediacom to significantly enhance the performance and lifespan of its existing DOCSIS infrastructure while maintaining a clear path to fiber evolution. A key differentiator of Harmonic’s cOS platform is its innovative PTP-less virtualized core, which allows Mediacom to launch DAA services without a timing network — increasing reliability, simplifying deployments and accelerating the rollout of broadband services.

“Mediacom is leading the charge toward DOCSIS 4.0, and their adoption of our cloud-native broadband software highlights the forward-thinking strategies top operators are embracing to modernize their networks,” said Nimrod Ben-Natan, CEO at Harmonic. “Our partnership with Mediacom paves the way for faster DOCSIS 4.0 rollouts, increased operational efficiency and a seamless transition to next-gen broadband.”

Harmonic is the market share leader in cable broadband equipment, virtual CMTS and DAA, according to Dell’Oro Group, the trusted source for market information about the telecommunications, networks and data center IT industries. The company’s market-leading cOS platform powers next-gen broadband services through more than 33 million customer premises equipment (CPE) devices worldwide for leading operators in North America, Europe, Latin America and Asia.

To learn more about Harmonic’s cOS platform and portfolio of network edge devices, visit www.harmonicinc.com/broadband.

About Harmonic
Harmonic (NASDAQ: HLIT), the worldwide leader in virtualized broadband and video delivery solutions, enables media companies and service providers to deliver ultra-high-quality video streaming and broadcast services to consumers globally. The company revolutionized broadband networking via the industry’s first virtualized broadband solution, enabling operators to more flexibly deploy gigabit internet services to consumers’ homes and mobile devices. Whether simplifying OTT video delivery via innovative cloud and software platforms, or powering the delivery of gigabit internet services, Harmonic is changing the way media companies and service providers monetize live and on-demand content on every screen. More information is available at www.harmonicinc.com. 

About Mediacom Communications Corporation
Mediacom Communications Corporation is the 5th largest cable operator in the United States and the leading gigabit broadband provider to smaller markets primarily in the Midwest and Southeast. Through its fiber-rich network, Mediacom offers high-speed data, video, phone, and mobile services to over 3 million households and businesses across 22 states. The company delivers scalable broadband solutions to commercial and public-sector customers of all sizes through Mediacom Business and sells advertising and production services under the OnMedia brand. More information about Mediacom is available at www.mediacomcable.com.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements concerning Harmonic’s business and the anticipated capabilities, advantages, reliability, efficiency, market acceptance, market growth, specifications and benefits of Harmonic products, services and technology are forward-looking statements. These statements are based on our current expectations and beliefs and are subject to risks and uncertainties, including the risks and uncertainties more fully described in Harmonic’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended Dec. 31, 2024, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K. The forward-looking statements in this press release are based on information available to Harmonic as of the date hereof, and Harmonic disclaims any obligation to update any forward-looking statements.

Harmonic, the Harmonic logo and other Harmonic marks are owned by Harmonic Inc. or its affiliates. All other trademarks referenced herein are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mediacom-communications-leads-broadband-innovation-with-unified-docsis-4-0-platform-from-harmonic-302485563.html

SOURCE Harmonic Inc.

C$ unless otherwise stated                                             TSX/NYSE/PSE: MFC     SEHK: 945

Ranks in top five for insurance industry overall

TORONTO
, June 23, 2025 /PRNewswire/ – Manulife has been ranked first in the life insurance sector for artificial intelligence (AI) maturity in the inaugural Evident AI Index for Insurance, ranking in the top five across the insurance industry overall, and is one of only three companies to rank in the top 10 in every category measured.

“We are incredibly proud to be recognized by Evident for our AI leadership. We were an early adopter of AI and have spent years embedding it across our business to deliver meaningful impact,” said Phil Witherington, President and CEO, Manulife. “At a time when our industry is experiencing a true inflection point for AI adoption, today’s recognition provides confidence that Manulife is on track to derive tangible growth, increased productivity, and financial performance gains through principled and disciplined deployment of AI across our business.”

The Evident AI Index for Insurance assesses AI maturity across 30 of the most prominent insurance companies in North America and Europe, measuring progress across four key categories: Talent, Innovation, Leadership, and Transparency.

Developed by AI benchmarking platform Evident, this first-of-its-kind index covers leading life, property and casualty, composite, and reinsurance groups, offering the most comprehensive benchmark of AI maturity in the insurance sector across North America and Europe.

“Being named the top life insurer for AI maturity is a reflection of how deeply we have embedded AI across our business,” said Jodie Wallis, Manulife’s Global Chief AI Officer. “We’ve integrated AI into the heart of our operations across the globe, and are delivering meaningful impact through responsible, practical AI deployments that drive results our customers and colleagues can feel. We are proud to have that commitment recognized by Evident.”

Manulife performed particularly well in the Leadership and Transparency categories, reflecting  strong support and enthusiasm from the executive leadership team and strategic investments in AI solutions across businesses and geographies, guided by the company’s Responsible AI Principles.

“Our Index highlights the insurers that are genuinely scaling AI capability and setting the bar for the wider industry, and as the leading life insurer Manulife is doing just that,” says Alexandra Mousavizadeh, Co-CEO and Co-founder of Evident. “Its strong performance, particularly around Leadership and Transparency, is a testament to Manulife’s multi-year investment into AI across the whole company.”

“This recognition reinforces our commitment to deploying AI at scale,” said Karen Leggett, Global Chief Marketing Officer for Manulife. “Manulife’s ranking on the Evident AI Index for Insurance validates that our AI initiatives are transforming the way we operate, developing solutions that create value across many parts of the organization and helping our customers live longer, healthier, wealthier lives.”

Manulife expects its digital investments and capabilities, including AI-enabled enhancements, to generate a threefold return on investment over five years through 2027, with over $600 million of benefits¹ realized in 2024 from our digital customer leadership initiatives globally.

Ms. Wallis is participating in The Evident AI Insurance Index Launch Roundtable on Tuesday, June 24^th between 10:00 – 11:00 am ET. If you are interested in attending virtually, please register online here: https://evidentinsights.com/events/the-evident-ai-insurance-index-launch-roundtable/ 

To learn more about Manulife’s AI progress, visit: manulife.com/AI

The full Evident AI Index report, and accompanying methodology, is available at https://evidentinsights.com/insurance-ai-index/. 

Caution regarding forward-looking statements

This document contains forward-looking statements within the meaning of the “safe harbour” provisions of Canadian provincial securities laws and the U.S. Private Securities Litigation Reform Act of 1995 with respect to Manulife’s use of its digital capabilities, including AI and AI-enabled tools, and the expected benefits it expects to realize. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from expectations include but are not limited to general business and economic conditions; changes in laws and regulations with respect to the use of AI-enabled tools; our ability to execute our digital plans and to deploy future digital use cases; our ability to adapt products and services to the changing market; our ability to attract and retain key employees; and our ability to protect our intellectual property and exposure to claims of infringement from others. Additional information about material risk factors that could cause actual results to differ materially from expectations may be found in our most recent annual and interim reports and elsewhere in our filings with Canadian and U.S. securities regulators.

The forward-looking statements in this document are, unless otherwise indicated, stated as of the date hereof. We do not undertake to update any forward-looking statements, except as required by law.

About Manulife  

Manulife Financial Corporation is a leading international financial services provider, helping our customers make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, providing financial advice and insurance for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2024, we had more than 37,000 employees, over 109,000 agents, and thousands of distribution partners, serving over 36 million customers. We trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges, and under ‘945’ in Hong Kong. 

Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com. 

Media Contact
Gina Simonis   
617-840-4794
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/manulife-named-1-life-insurance-company-for-ai-maturity-by-evident-302487676.html

SOURCE Manulife Financial Corporation

RESTON, Va.
, June 23, 2025 /PRNewswire/ — A Leidos-led (NYSE: LDOS) modernization initiative, involving companies from France, Germany, Italy, and the U.K., aims to enhance NATO’s IT infrastructure. The project is designed to improve resilience against cyber threats and increase efficiency and scalability, in support of NATO digital transformation.

Leidos was awarded a contract from the NATO Communications and Information Agency (NCIA) for the provision of a centralized IT solution (based on private cloud technology) to support NATO’s operational network, integrating core services such as service management and cybersecurity with the goal of enhancing interoperability and operational efficiency across the NATO command structure.

“This project reflects our long-standing commitment to NATO, leveraging innovative solutions aimed at delivering secure, mission-ready capabilities designed to adapt with operational needs,” said Steve Hull, Leidos digital modernization sector president. “It also creates new opportunities for more integrated collaboration across trans-Atlantic defense networks, helping NATO teams stay securely connected and able to share critical information with greater speed, agility and assurance.”

Thales (France), CGI (Germany), Leonardo (Italy), LA International (U.K.) and NEXOR (U.K.) are joining Leidos as a multi-national team with extensive knowledge of NATO requirements and a strong track record of delivering results. Collectively, they have supported NATO’s work for decades.

The IT Modernization Recovery Increment 1 Systems Integration contract bolsters Leidos’ role as a key technology partner with NCIA, supporting NATO’s mission and advancing secure cloud modernization. It has a ceiling value of $87 million (€79.1 million) on indefinite delivery indefinite quantity (IDIQ) firm-fixed price terms.  

About Leidos

Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with 47,000 global employees, Leidos reported annual revenues of approximately $16.7 billion for the fiscal year ended January 3, 2025. For more information, visit www.leidos.com.

Certain statements in this announcement constitute “forward-looking statements” within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management’s current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the “Risk Factors” set forth in Leidos’ Annual Report on Form 10-K for the fiscal year ended January 3, 2025, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.

Media Contact:

Brandon Ver Velde

(571) 526-6257
[email protected]

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/leidos-global-partners-to-boost-nato-capabilities-through-cloud-modernization-302487368.html

SOURCE Leidos Holdings, Inc.

PHOENIX
, June 23, 2025 /PRNewswire/ — Trinity Capital Inc. (Nasdaq: TRIN) (“Trinity Capital”), a leading alternative asset manager, today announced the commitment of $15 million in growth capital to K2view, an enterprise data management innovator powering operational data products for generative AI.

Founded in 2009, K2view helps global enterprises – including brands in financial services, telecom, healthcare, and retail – unify fragmented data across systems to deliver secure, real-time data products at scale. The K2view Data Product Platform supports a growing number of operational use cases, including data integration and cloud migration, x360, test data management, synthetic data generation, and enterprise data for agentic AI.

“K2view is at the forefront of solving a critical bottleneck in the enterprise adoption of generative AI,” said Jack McNamara, Director of Tech Lending at Trinity Capital. “The company’s differentiated approach to data products is delivering transformative results for Fortune 1000 customers, and we’re excited to support their next stage of growth.”

The company’s platform is actively powering AI-assisted customer experiences for prominent telecom operators. This capital will accelerate K2view’s growth and innovation in the rapidly evolving space of enterprise data infrastructure for generative and agentic AI.

“We’re thrilled to partner with Trinity Capital as we continue our mission to unlock the power of enterprise data for agentic AI,” said Ronen Schwartz, CEO of K2view. “This growth capital will allow us to accelerate product innovation, scale go-to-market initiatives, and help more organizations deploy fast, secure, and contextualized AI applications.”

About Trinity Capital Inc.

Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies. With five distinct business verticals–Sponsor Finance, Equipment Finance, Tech Lending, Asset-Based Lending, and Life Sciences–Trinity Capital stands as a long-term trusted partner for innovative companies seeking tailored debt solutions. Headquartered in Phoenix, Arizona, Trinity Capital’s dedicated team is strategically located across the United States and in London (UK). For more information on Trinity Capital, please visit


trinitycapital.com


 and stay connected to the latest activity via


LinkedIn


 and


X


 (@trincapital).

About K2view
K2view delivers a Data Product Platform that guarantees enterprise data is always AI-ready – making it protected, complete, and instantly accessible. The platform packages AI-ready datasets as data products, enabling reuse at scale across a wide range of use cases, including Agentic AI, Synthetic Data Generation, Test Data Management, and Cloud Migration.

Some of the world’s largest organizations rely on K2view, including AT&T, Regions Bank, Sun Life, BBVA, Hapag-Lloyd, Vodafone, and Verizon.

Gartner recognized K2view as a Visionary in the Data Integration Tools Magic Quadrant – proof that the company’s bold approach to data is delivering value today and shaping what’s next.

Learn more at www.k2view.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-provides-k2view-with-15-million-to-meet-surging-demand-for-agentic-ai-data-infrastructure-302487784.html

SOURCE Trinity Capital Inc.

Firm recognized for exceptional business integrity and best-in-class ethics

CHICAGO
, June 23, 2025 /PRNewswire/ — JLL (NYSE: JLL) announced today that it has earned the coveted Compliance Leader Verification from Ethisphere, a global leader in defining and advancing the standards of ethical business practices.

“At JLL, our ethics program empowers every employee to be a guardian of our ethical standards where trust, fairness and accountability are the foundation of our daily operations,” said Alan Tse, Chief Legal Officer and Corporate Secretary for JLL. “Ethics is at the heart of our culture, underpinning every part of our business and helping us achieve our purpose of shaping the future of real estate for a better world.”

JLL’s performance was evaluated on six key areas: program resources and structure; perceptions of ethical culture; written standards; training and communication; risk assessment, monitoring and auditing; and enforcement, discipline, and incentives.

“This Compliance Leader Verification reflects JLL’s larger march to excellence,” says Jodie Fredericksen, Senior Compliance Counsel, Ethisphere. “JLL understands that having a good ethics and compliance program that is externally recognized is a business differentiator and they do an excellent job of showing how their continued commitment to business integrity improves their business.”

More information about Compliance Leader Verification is available on Ethisphere’s website. Learn more about JLL’s best-in-class ethics program here.

About Ethisphere 
Ethisphere® is the global leader in defining and advancing the standards of ethical business practices that fuel corporate character, marketplace trust, and business success. Ethisphere has deep expertise in measuring and defining core ethics standards using data-driven insights that help companies enhance corporate character. Ethisphere honors superior achievement through its World’s Most Ethical Companies® recognition program, provides a community of industry experts with the Business Ethics Leadership Alliance (BELA), and showcases trends and best practices in ethics with Ethisphere Magazine. Ethisphere also helps to advance business performance through data-driven assessments, benchmarking, and guidance. Learn more about Ethisphere at https://www.ethisphere.com.

About JLL
For over 200 years, JLL (NYSE: JLL), a leading global commercial real estate and investment management company, has helped clients buy, build, occupy, manage and invest in a variety of commercial, industrial, hotel, residential and retail properties. A Fortune 500 company with annual revenue of $23.4 billion and operations in over 80 countries around the world, our more than 112,000 employees bring the power of a global platform combined with local expertise. Driven by our purpose to shape the future of real estate for a better world, we help our clients, people and communities SEE A BRIGHTER WAY^SM. JLL is the brand name, and a registered trademark, of Jones Lang LaSalle Incorporated. For further information, visit jll.com.

Contact: Allison Heraty
Phone: +1 312 228 3128
Email: [email protected]

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/jll-earns-ethispheres-compliance-leader-verification-302487351.html

SOURCE JLL-IR